Pacific Biosciences Of Stock EBITDA
| PACB Stock | USD 1.83 0.10 5.18% |
Pacific Biosciences of fundamentals help investors to digest information that contributes to Pacific Biosciences' financial success or failures. It also enables traders to predict the movement of Pacific Stock. The fundamental analysis module provides a way to measure Pacific Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pacific Biosciences stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -277.3 M | -263.4 M |
Pacific | EBITDA |
Pacific Biosciences of Company EBITDA Analysis
Pacific Biosciences' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Pacific Biosciences EBITDA | (277.28 M) |
Most of Pacific Biosciences' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pacific Biosciences of is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Pacific EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Pacific Biosciences is extremely important. It helps to project a fair market value of Pacific Stock properly, considering its historical fundamentals such as EBITDA. Since Pacific Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pacific Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pacific Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Pacific Ebitda
Ebitda |
|
According to the company disclosure, Pacific Biosciences of reported earnings before interest,tax, depreciation and amortization of (277.28 Million). This is 131.6% lower than that of the Life Sciences Tools & Services sector and 143.15% lower than that of the Health Care industry. The ebitda for all United States stocks is 107.11% higher than that of the company.
Pacific EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pacific Biosciences' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pacific Biosciences could also be used in its relative valuation, which is a method of valuing Pacific Biosciences by comparing valuation metrics of similar companies.Pacific Biosciences is currently under evaluation in ebitda category among its peers.
Pacific Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Pacific Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Pacific Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Pacific Biosciences' value.| Shares | Bank Of New York Mellon Corp | 2024-09-30 | 5.6 M | Goldman Sachs Group Inc | 2024-09-30 | 4.2 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 3.9 M | Capital World Investors | 2024-09-30 | 3.4 M | Northern Trust Corp | 2024-09-30 | 2.4 M | Marshall Wace Asset Management Ltd | 2024-09-30 | 2.1 M | Soros Fund Management Llc | 2024-09-30 | 2.1 M | Charles Schwab Investment Management Inc | 2024-09-30 | 2 M | Bank Of America Corp | 2024-06-30 | 1.9 M | Ark Investment Management Llc | 2024-09-30 | 33.4 M | Blackrock Inc | 2024-06-30 | 23.6 M |
Pacific Fundamentals
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (2.28) % | ||||
| Operating Margin | (1.40) % | ||||
| Current Valuation | 1.01 B | ||||
| Shares Outstanding | 294.32 M | ||||
| Shares Owned By Insiders | 9.32 % | ||||
| Shares Owned By Institutions | 83.08 % | ||||
| Number Of Shares Shorted | 52.14 M | ||||
| Price To Earning | 197.88 X | ||||
| Price To Book | 1.24 X | ||||
| Price To Sales | 3.28 X | ||||
| Revenue | 200.52 M | ||||
| Gross Profit | 53.47 M | ||||
| EBITDA | (277.28 M) | ||||
| Net Income | (306.74 M) | ||||
| Cash And Equivalents | 834.34 M | ||||
| Cash Per Share | 3.69 X | ||||
| Total Debt | 933.93 M | ||||
| Debt To Equity | 1.51 % | ||||
| Current Ratio | 11.19 X | ||||
| Book Value Per Share | 1.66 X | ||||
| Cash Flow From Operations | (259.17 M) | ||||
| Short Ratio | 4.85 X | ||||
| Earnings Per Share | (1.46) X | ||||
| Price To Earnings To Growth | (0.17) X | ||||
| Target Price | 3.02 | ||||
| Number Of Employees | 796 | ||||
| Beta | 2.01 | ||||
| Market Capitalization | 568.03 M | ||||
| Total Asset | 1.75 B | ||||
| Retained Earnings | (1.84 B) | ||||
| Working Capital | 647.02 M | ||||
| Current Asset | 110.54 M | ||||
| Current Liabilities | 38.18 M | ||||
| Net Asset | 1.75 B |
About Pacific Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pacific Biosciences of's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pacific Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pacific Biosciences of based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Pacific Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Pacific Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pacific Biosciences Of Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pacific Biosciences Of Stock:Check out Pacific Biosciences Piotroski F Score and Pacific Biosciences Altman Z Score analysis. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacific Biosciences. If investors know Pacific will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacific Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.46) | Revenue Per Share 0.64 | Quarterly Revenue Growth (0.28) | Return On Assets (0.11) | Return On Equity (0.65) |
The market value of Pacific Biosciences is measured differently than its book value, which is the value of Pacific that is recorded on the company's balance sheet. Investors also form their own opinion of Pacific Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Pacific Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacific Biosciences' market value can be influenced by many factors that don't directly affect Pacific Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pacific Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacific Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacific Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.